I would like to discuss the methodology and effectiveness of using Raman spectroscopy to distinguish between cystic fibrosis patients undergoing elexacaftor/tezacaftor/ivacaftor (ETI) therapy and non-treated patients, specifically by analyzing serum lipid biomarkers.